Information
291-13 Dongbu-daero, Jinwi-myeon, Pyeongtaek, Gyeonggi-do, South Korea
-
-
-
Overview
- Summary
- Seers Technology is a specialized company in digital healthcare solutions utilizing wearable biosensors, central patient monitoring systems, and medical artificial intelligence technologies. The company supports integrated smart medical services, providing practical solutions for medical systems based on proven end-to-end technological capabilities. It develops, produces, and sells AI-based diagnostic and monitoring platforms, being the first medical AI company in Korea to achieve annual profitability. The company aims to offer comprehensive medical services covering prevention, examination, treatment, and monitoring throughout the patient's entire care cycle.Seers Technology is a specialized company in digital healthcare solutions utilizing wearable biosensors, central patient monitoring systems, and medical artificial intelligence technologies. The company supports integrated smart medical services, providing practical solutions for medical systems based on proven end-to-end technological capabilities. It develops, produces, and sells AI-based diagnostic and monitoring platforms, being the first medical AI company in Korea to achieve annual profitability. The company aims to offer comprehensive medical services covering prevention, examination, treatment, and monitoring throughout the patient's entire care cycle.
- Key Products/Technologies
- mobiCARE™: A wearable ECG patch-based solution for arrhythmia diagnosis and monitoring. It incorporates an AI algorithm that autonomously identifies and clusters noise, waveform distortions, and abnormal signals from long-term collected ECG data, enhancing the reliability of analysis results. This product holds the top market share in Korea for wearable ECG analysis services, implemented in over 840 medical institutions, including tertiary hospitals. The company is preparing for entry into the US market, with the FDA 510K approval process currently underway.mobiCARE™: A wearable ECG patch-based solution for arrhythmia diagnosis and monitoring. It incorporates an AI algorithm that autonomously identifies and clusters noise, waveform distortions, and abnormal signals from long-term collected ECG data, enhancing the reliability of analysis results. This product holds the top market share in Korea for wearable ECG analysis services, implemented in over 840 medical institutions, including tertiary hospitals. The company is preparing for entry into the US market, with the FDA 510K approval process currently underway.
- thynC™: A real-time patient monitoring platform designed for hospitalized patients. It collects vital signs such as ECG, SpO2, blood pressure, and temperature in real-time via wearable sensors, transmitting them to medical staff. The system utilizes AI-based analysis to detect abnormal signs early and provide alerts, simultaneously improving medical staff efficiency and patient safety. It is the first in Korea to secure health insurance coverage (EX871) for ECG monitoring, lowering hospital adoption barriers and contributing to revenue growth.thynC™: A real-time patient monitoring platform designed for hospitalized patients. It collects vital signs such as ECG, SpO2, blood pressure, and temperature in real-time via wearable sensors, transmitting them to medical staff. The system utilizes AI-based analysis to detect abnormal signs early and provide alerts, simultaneously improving medical staff efficiency and patient safety. It is the first in Korea to secure health insurance coverage (EX871) for ECG monitoring, lowering hospital adoption barriers and contributing to revenue growth.
- Medical Artificial Intelligence (AI) Technology: Development of various disease prediction and diagnostic support algorithms, including atrial fibrillation prediction, EMR-based cardiac arrest prediction, 3-lead ECG analysis for various heart diseases, emergency arrhythmia prediction, heart failure exacerbation prediction, ovulation cycle prediction, and sleep apnea prediction. The company possesses world-class medical AI technology, evidenced by numerous publications in top 10% JCR international journals.Medical Artificial Intelligence (AI) Technology: Development of various disease prediction and diagnostic support algorithms, including atrial fibrillation prediction, EMR-based cardiac arrest prediction, 3-lead ECG analysis for various heart diseases, emergency arrhythmia prediction, heart failure exacerbation prediction, ovulation cycle prediction, and sleep apnea prediction. The company possesses world-class medical AI technology, evidenced by numerous publications in top 10% JCR international journals.
- Wearable Biosensors and Medical Adhesive Materials: Establishment of an integrated medical device production infrastructure that manages the entire process from research to production of wearable biosensors, patient monitoring software, and medical adhesive materials. This proprietary technology forms the basis of product competitiveness and ensures a stable supply chain.Wearable Biosensors and Medical Adhesive Materials: Establishment of an integrated medical device production infrastructure that manages the entire process from research to production of wearable biosensors, patient monitoring software, and medical adhesive materials. This proprietary technology forms the basis of product competitiveness and ensures a stable supply chain.
- Core Advantages
- In-house Technology and End-to-End Solution Capability: Self-production of core products for data digitalization, offering comprehensive end-to-end solutions for patient monitoring, including wearable medical devices, virtual care gateways, clinical support algorithms, mobile apps, web applications, and cloud servers.In-house Technology and End-to-End Solution Capability: Self-production of core products for data digitalization, offering comprehensive end-to-end solutions for patient monitoring, including wearable medical devices, virtual care gateways, clinical support algorithms, mobile apps, web applications, and cloud servers.
- Advanced AI Algorithms and Clinical Evidence: Continuous advancement of AI algorithms, such as those that learn multi-layered ECG data over time and track pattern changes before arrhythmia onset for prediction. The company possesses the largest volume of clinical research results in Korea, providing highly reliable analysis.Advanced AI Algorithms and Clinical Evidence: Continuous advancement of AI algorithms, such as those that learn multi-layered ECG data over time and track pattern changes before arrhythmia onset for prediction. The company possesses the largest volume of clinical research results in Korea, providing highly reliable analysis.
- Commercialization Based on Insurance Coverage and Subscription Business Model: The first in Korea to secure national health insurance coverage for ECG inpatient monitoring, which lowers initial adoption barriers for hospitals and establishes a stable recurring revenue model. Health insurance application ensures hospital profitability, strengthening market dominance.Commercialization Based on Insurance Coverage and Subscription Business Model: The first in Korea to secure national health insurance coverage for ECG inpatient monitoring, which lowers initial adoption barriers for hospitals and establishes a stable recurring revenue model. Health insurance application ensures hospital profitability, strengthening market dominance.
- Strategic Partnerships and Distribution Network: Collaboration with leading domestic pharmaceutical company Daewoong Pharmaceutical for distribution and sales, accelerating market penetration in Korea. Partnership with PureHealth Group, a UAE state-owned medical group, for Middle East market entry and national arrhythmia screening system establishment. Strategic MOU with Ray for Australian market entry, expanding international networks.Strategic Partnerships and Distribution Network: Collaboration with leading domestic pharmaceutical company Daewoong Pharmaceutical for distribution and sales, accelerating market penetration in Korea. Partnership with PureHealth Group, a UAE state-owned medical group, for Middle East market entry and national arrhythmia screening system establishment. Strategic MOU with Ray for Australian market entry, expanding international networks.
- Regulatory Foundation for Global Market Entry: Acquisition of Medical Device Single Audit Program (MDSAP) certification, streamlining complex regulatory procedures for market entry in key countries such as Australia, Canada, Japan, and Brazil. US patent registration and ongoing FDA approval efforts strengthen the legal basis for US market entry.Regulatory Foundation for Global Market Entry: Acquisition of Medical Device Single Audit Program (MDSAP) certification, streamlining complex regulatory procedures for market entry in key countries such as Australia, Canada, Japan, and Brazil. US patent registration and ongoing FDA approval efforts strengthen the legal basis for US market entry.
- Market Leadership and Successful Turnaround to Profitability: Holds the number one market share in Korea for wearable ECG analysis services. The first medical AI company in Korea to achieve annual profitability, demonstrating business viability and revenue stability.Market Leadership and Successful Turnaround to Profitability: Holds the number one market share in Korea for wearable ECG analysis services. The first medical AI company in Korea to achieve annual profitability, demonstrating business viability and revenue stability.
- Target Industrie
- Healthcare and Bio IndustryHealthcare and Bio Industry
- Hospitals (Tertiary, General, Primary Medical Institutions)Hospitals (Tertiary, General, Primary Medical Institutions)
- Health Checkup CentersHealth Checkup Centers
- Smart Ward ImplementationSmart Ward Implementation
- Remote Patient MonitoringRemote Patient Monitoring
- Long-term Care FacilitiesLong-term Care Facilities
- Major Markets
- North Africa (including MENA region)North Africa (including MENA region)
- United Arab Emirates (UAE), Hong Kong, Vietnam, Kazakhstan, Mongolia, India, IndonesiaUnited Arab Emirates (UAE), Hong Kong, Vietnam, Kazakhstan, Mongolia, India, Indonesia
- United States (US) (FDA approval and market entry preparation underway)United States (US) (FDA approval and market entry preparation underway)
- Australia (MDSAP-compliant country, collaboration with Ray)Australia (MDSAP-compliant country, collaboration with Ray)
- Brazil (MDSAP-compliant country)Brazil (MDSAP-compliant country)
- Certifications/Patents
- US Patent: Registered for 'Method and Apparatus for Correcting Electrocardiogram'.US Patent: Registered for 'Method and Apparatus for Correcting Electrocardiogram'.
- Domestic Patent: Registered for AI-based arrhythmia stage prediction.Domestic Patent: Registered for AI-based arrhythmia stage prediction.
- MDSAP (Medical Device Single Audit Program) Certification acquired.MDSAP (Medical Device Single Audit Program) Certification acquired.
- MFDS (Korean Ministry of Food and Drug Safety) approval for mobiCARE ECG patch.MFDS (Korean Ministry of Food and Drug Safety) approval for mobiCARE ECG patch.
- CE MDD (European Medical Device Directive) certification for remote medical devices (HX-461) and mobiCARE ECG patch.CE MDD (European Medical Device Directive) certification for remote medical devices (HX-461) and mobiCARE ECG patch.
- FDA Special 510(k) certification for remote medical devices (HX-461).FDA Special 510(k) certification for remote medical devices (HX-461).
- ISO 9001, 14001, 13485 (Medical Device Quality Management System) certifications.ISO 9001, 14001, 13485 (Medical Device Quality Management System) certifications.
- GMP (Good Manufacturing Practice) certification for medical devices and medical device manufacturing license acquired.GMP (Good Manufacturing Practice) certification for medical devices and medical device manufacturing license acquired.
- Ministry of Knowledge Economy certification as a specialized parts and materials company, and R&D-oriented venture company certification.Ministry of Knowledge Economy certification as a specialized parts and materials company, and R&D-oriented venture company certification.
- Sony Green Partner certification, Apple 'MFI (Made for iPhone/iPod/iPad)' license acquired.Sony Green Partner certification, Apple 'MFI (Made for iPhone/iPod/iPad)' license acquired.
- Recipient of the Minister of SMEs and Startups Award in the New Technology category at the 2025 Korea Medical AI Industry Awards.Recipient of the Minister of SMEs and Startups Award in the New Technology category at the 2025 Korea Medical AI Industry Awards.
Introduction
Location
291-13 Dongbu-daero, Jinwi-myeon, Pyeongtaek, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
